A life sciences firm building non-invasive saliva-based biosensors, like a glucose monitor for diabetics that avoids finger pricks, plus a COVID-19 diagnostic tool.
No revenue recorded (USD 0.00B annually); gross margin is 48.63% but net margin is -294.91%, meaning it burns cash with no sales yet.
No visible moat—its biosensor tech faces direct competition from established players like Abbott and Roche, and without revenue or patents cited, nothing stops them from replicating the approach.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
